Analyst Price Target is $26.50
▲ +161.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Icosavax in the last 3 months. The average price target is $26.50, with a high forecast of $28.00 and a low forecast of $25.00. The average price target represents a 161.86% upside from the last price of $10.12.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Icosavax. This Buy consensus rating has held steady for over two years.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.